When the NIH canceled grants in March related to diversity, equity and inclusion, or DEI, some Alzheimer’s studies were swept ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why BIIB stock is a hold.

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

Biogen BIIB will report first-quarter 2025 results on May 1, before market open. In the last reported quarter, the company's ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

A phase I/II trial showed that transplanting dopaminergic progenitors derived from induced pluripotent stem cells was safe in ...

Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | The Trump administration is expected to announce tariffs on pharmaceuticals ...

An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now caught ...

On Monday, 74-year-old Ralph Carmona of Portland will be the only qualified Boston Marathon runner with Alzheimer's.

Patients will lose access to cheaper versions of the blockbuster drugs after the agency shuts down the multibillion-dollar industry now that the drug shortage has ended. Also in the news: Eli Lilly's ...